Kenneth E Truitt

Title: The Innovations of Kenneth E. Truitt

Introduction

Kenneth E. Truitt is a notable inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the development of human lymphoblastoid cell lines and hybridomas. His work has led to advancements in monoclonal antibody production, which has important implications for medical research and treatment.

Latest Patents

Kenneth E. Truitt holds 2 patents. His latest patents include a description of a 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2. This subvariant line, designated LTR228, is noted for its efficient fusion with human cells. Additionally, the human.times.human hybridomas derived from LTR228 produce monoclonal antibodies against tetanus toxin and blood group A, showcasing the potential applications of his research.

Career Highlights

Truitt has had a distinguished career, working at Cetus Corporation, where he has been able to apply his innovative ideas in a collaborative environment. His work has not only advanced scientific understanding but has also contributed to practical applications in medicine.

Collaborations

Throughout his career, Kenneth E. Truitt has collaborated with esteemed colleagues such as James W. Larrick and Andrew R. Raubitschek. These collaborations have further enriched his research and expanded the impact of his inventions.

Conclusion

Kenneth E. Truitt's contributions to biotechnology through his patents and collaborations have made a lasting impact on the field. His innovative work continues to influence medical research and applications today.